| Code | CSB-RA005036MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to RG6125, targeting CDH11 (Cadherin-11), also known as OB-cadherin. CDH11 is a type II classical cadherin that mediates homophilic cell-cell adhesion and plays critical roles in tissue morphogenesis, cellular migration, and maintenance of tissue architecture. This calcium-dependent adhesion molecule is prominently expressed in mesenchymal cells, including fibroblasts and osteoblasts. CDH11 has been implicated in various pathological conditions, particularly fibrotic diseases such as pulmonary fibrosis and systemic sclerosis, where it promotes fibroblast activation and tissue remodeling. Additionally, CDH11 contributes to rheumatoid arthritis pathogenesis by mediating synovial fibroblast adhesion and inflammatory joint destruction, and has been associated with cancer metastasis and tumor progression.
RG6125 is a therapeutic antibody developed by Roche/Genentech that specifically blocks CDH11-mediated cellular interactions. This biosimilar provides researchers with a valuable tool for investigating CDH11 biology, fibrotic mechanisms, inflammatory processes, and potential therapeutic interventions in preclinical models of fibrosis, arthritis, and oncology.
There are currently no reviews for this product.